Company intelligence / Profile preview

Ribocure Pharmaceuticals AB

Gothenburg, Sweden

Ownership: Public · 06938.HK
Employees: ~20
Development stage: Phase 2

Overview

Patient enrollment for RBD4059's phase 2a trial for coronary artery disease in Sweden was completed in February 2025. RBD5044's phase 2 trial was initiated in Sweden in January 2025 for patients with mixed dyslipidemia. Patient enrollment for RBD1016's phase 2 global MRCT for treating CHB was completed in November 2024.

Therapeutic areas: CardiovascularMetabolic DisordersNephrologyOncologyRare Diseases
Modalities: RNA therapeuticssiRNAoligonucleotide therapeutics
Industry: Biotech

Drug pipeline

1 asset

RBD5044

Phase 2

Indications: Mixed dyslipidemia

Partnerships

Boehringer IngelheimPheironMedtanken Group ABQilu Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Ribocure Pharmaceuticals AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribocure Pharmaceuticals AB.

Explore the full profile